BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 28632888)

  • 1. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
    Erduran F; Adışen E; Aksakal AB
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tofacitinib in treatment of alopecia universalis in two patients.
    Gupta AK; Carviel JL; Abramovits W
    J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1373-8. PubMed ID: 27306107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
    Bokhari L; Sinclair R
    Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
    Brown L; Skopit S
    J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient.
    Patel NU; Oussedik E; Grammenos A; Pichardo-Geisinger R
    J Cutan Med Surg; 2018; 22(4):439-442. PubMed ID: 29463114
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
    Dincer D; Tanacan E; Kose Ozkan C
    J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alopecia universalis. Partial response to tofacitinib.
    Ruiz-Villaverde R; Cuenca-Barrales C; Linares-Gonzalez L; Ródenas-Herranz T
    Med Clin (Barc); 2019 Aug; 153(3):e15. PubMed ID: 30718001
    [No Abstract]   [Full Text] [Related]  

  • 14. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment.
    Kim BY; Kim HS
    Singapore Med J; 2017 May; 58(5):279-280. PubMed ID: 28536724
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
    Scheinberg M; Ferreira SB
    Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
    [No Abstract]   [Full Text] [Related]  

  • 18. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
    Shivanna CB; Shenoy C; Priya RA
    Int J Trichology; 2018; 10(3):103-107. PubMed ID: 30034188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 20. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
    Craiglow BG; King BA
    J Invest Dermatol; 2014 Dec; 134(12):2988-2990. PubMed ID: 24940651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.